Multiple small-molecule kinase inhibitors with specific molecular targets have recently been developed for the treatment of cancer. This article reports the development and validation of an ultra-performance liquid chromatography/tandem mass spectrometry (UPLC–MS/MS) method to simultaneously analyse the small-molecule kinase inhibitors dacomitinib, ceritinib, lorlatinib, and nintedanib in human plasma. For chromatographic analyte separation, an Acquity UPLC® BEH C18 column 1.7 μm, 50 mm x 2.1 mm was used with a binary gradient of pure water/formic acid/ammonium formate (100:0.1:0.02, v/v/v) and methanol/formic acid (100:0.1, v/v). Calibration curves for all small-molecule kinase inhibitors were 5.00–500 ng/mL. Validation of this method met all requirements of the Food and Drug administration. Additionally, clinical applicability was demonstrated by quantification of multiple samples from a pharmacokinetic study in patients with lung cancer.

Ceritinib, Dacomitinib, Lorlatinib, Nintedanib, Small-molecule kinase inhibitor (SMKI), Ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS),
Journal of Pharmaceutical and Biomedical Analysis
Department of Medical Oncology

Veerman, G.D.M, de Bruijn, P.J, Dingemans, A.-M.C. (Anne-Marie C.), Mathijssen, A.H.J, & Koolen, S.L.W. (2021). To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 193. doi:10.1016/j.jpba.2020.113733